cysteamine

(redirected from Procysbi)
Also found in: Medical.

cysteamine

(sɪsˈtiːəmɪn)
n
a drug used to treat cystine excretion or radiation sickness
References in periodicals archive ?
Horizon Pharma plc (Horizon), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed the sale of a European subsidiary that owns the marketing rights to PROCYSBI (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin nebuliser solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.
It also adds Procysbi delayed-release capsules and Quinsair (aerosolized form of levofloxacin) global rights, with Procysbi having strong patent protection through 2034.
The most prominent drugs in Raptor's portfolio are Procysbi, used to reduce the toxic concentration of cystine in cells, and Quinsair, approved in the European Union and in Canada for the management of chronic pulmonary infections due to the presence of Pseudomonas aeruginosa bacterium in adult patients with cystic fibrosis.
It adds Procysbi delayed-release capsules and Quinsair (aerosolised form of levofloxacin) global rights, with Procysbi having strong patent protection through 2034.
M2 PHARMA-September 13, 2013-Raptor Pharmaceuticala[euro](tm)s PROCYSBI granted marketing authorisation in EU(C)2013 M2 COMMUNICATIONS
The commercial products are PROCYSBI (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin inhalation solution).
M2 EQUITYBITES-September 13, 2013-Raptor Pharmaceuticala[euro](tm)s PROCYSBI granted marketing authorisation in EU(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-September 13, 2013-Raptor Pharmaceutical Corp awarded marketing approval for PROCYSBI for proven nephropathic cystinosis in the EU(C)2013 M2 COMMUNICATIONS
The acquisition sees the addition of Procysbi, a treatment for nephropathic cystinosis, a rare metabolic disorder, and Quinsair, which is given to cystic fibrosis patients, to Horizons rare disease portfolio.
M2 EQUITYBITES-September 13, 2013-Raptor Pharmaceutical Corp awarded marketing approval for PROCYSBI for proven nephropathic cystinosis in the EU(C)2013 M2 COMMUNICATIONS http://www.
Biopharmaceutical company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) reported on Monday the receipt of a positive opinion from the European Union (EU) Committee for Orphan Medicinal Products (COMP) recommending orphan drug exclusivity for PROCYSBI (mercaptamine) gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis.
PROCYSBI is the first cystine-depleting agent given every 12 hours that is approved in the United States for the treatment of nephropathic cystinosis (NC), a rare metabolic disorder, in adults and children 2 years of age and older.